In the third quarter of 2026, the Phase II study for diabetes treatment is anticipated to reveal its topline data. The ASC30 showed promising results with a placebo-adjusted weight loss of a maximum of 7.7% in a 13-week U.S. Phase II study involving individuals struggling with obesity or being overweight. This indicates a significant improvement in managing weight-related issues.